Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib +/- Cytarabine in AML, MDS, and MF
NCT03718143Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- May 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adavosertib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myelofibrosis (MF) (3 arms), sponsored by NYU Langone Health. Primary endpoint: Complete Remission Rate at 4 months. Started May 2019; status: terminated.
02
Drugs
adavosertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03718143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718143.